The estimated Net Worth of Harout Semerjian is at least $4 mil dollars as of 11 November 2022. Mr Semerjian owns over 25,000 units of GlycoMimetics Inc stock worth over $4,000 and over the last 5 years he sold GLYC stock worth over $0.
Mr has made over 1 trades of the GlycoMimetics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 25,000 units of GLYC stock worth $32,250 on 11 November 2022.
The largest trade he's ever made was buying 25,000 units of GlycoMimetics Inc stock on 11 November 2022 worth over $32,250. On average, Mr trades about 5,000 units every 0 days since 2020. As of 11 November 2022 he still owns at least 25,000 units of GlycoMimetics Inc stock.
You can see the complete history of Mr Semerjian stock trades at the bottom of the page.
Harout Semerjian is the CEO, Pres & Director at GlycoMimetics Inc.
Mr Semerjian is 51, he's been the CEO y Pres & Director of GlycoMimetics Inc since . There are 11 older and 3 younger executives at GlycoMimetics Inc. The oldest executive at GlycoMimetics Inc is Dr. John L. Magnani, 68, who is the Sr. VP of Research & Chief Scientific Officer.
Harout's mailing address filed with the SEC is C/O GLYCOMIMETICS, INC, 9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850.
Over the last 11 years, insiders at GlycoMimetics Inc have traded over $15,299,593 worth of GlycoMimetics Inc stock and bought 10,868,557 units worth $48,421,008 . The most active insiders traders include Scott D Sandell, Peter J Barris y M James Barrett. On average, GlycoMimetics Inc executives and independent directors trade stock every 51 days with the average trade being worth of $38,210. The most recent stock trade was executed by Public Equities, L.P.Invus ... on 7 August 2024, trading 322,361 units of GLYC stock currently worth $61,249.
at glycomimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments. glycomimetics is a clinical-stage biotechnology company. we use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. since the company’s inception in 2003, we have developed a robust, diversified product pipeline. we are a public company traded on the nasdaq under the symbol glyc.
GlycoMimetics Inc executives and other stock owners filed with the SEC include: